Literature DB >> 16256076

Use of [3H]fluorowillardiine to study properties of AMPA receptor allosteric modulators.

Markus Kessler1, Amy C Arai.   

Abstract

Compounds which modulate AMPA receptor function through allosteric mechanisms were examined for their effect on the binding of the agonist [3H]fluorowillardiine (FW). Benzamide-type positive modulators (ampakinestrade mark) under all experimental circumstances increased [3H]FW binding to native receptors in rat brain membranes. Benzothiadiazide drugs had more variable effects ranging from large reductions with cyclothiazide and JM-13 to increases produced by more recent compounds like PEPA, D1 and LY392098. These effects on binding were moderately influenced by the assay conditions, including temperature and the presence or absence of thiocyanate. Significant changes in agonist binding were also produced by other modulatory agents such as noncompetitive blockers (GYKI 53655, SYM 2206), polycationic compounds (spermine, Naspm, philanthotoxin) and polyanionic compounds (Evans Blue, suramin, PPNDS). EC50 values usually were similar to those from physiological studies, which validates using binding tests to assess drug potencies. Moreover, direction and magnitude of the binding change (Emax) provide information about which kinetic aspects are affected by a drug. For example, the magnitude of the binding increase produced by positive modulators was strongly correlated with their ability to slow response deactivation in excised patch recordings. Binding also provides a reliable method to examine whether interactions between agents are competitive. Thus, thiocyanate did not significantly influence the EC50 of cyclothiazide, suggesting distinct sites of action. Taken together, [3H]FW binding can yield important information about drug-receptor and drug-drug interactions for a wide range of modulatory agents. One potential limitation of [3H]FW is a large preference for subunits GluR1 and GluR2 (KD 4-10 nM) over GluR3 and GluR4 (160-600 nM) which implies that tests with brain membranes preferentially reveal drug effects produced at the former two subunits. Lastly, data are shown which highlight the importance of optimizing experimental conditions in filtration assays, for instance by always including thiocyanate in wash buffers.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16256076     DOI: 10.1016/j.brainres.2005.09.024

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  10 in total

1.  Physiological significance of high- and low-affinity agonist binding to neuronal and recombinant AMPA receptors.

Authors:  Markus Kessler; Erika Suzuki; Kyle Montgomery; Amy C Arai
Journal:  Neurochem Int       Date:  2008-03-08       Impact factor: 3.921

Review 2.  Multiple roles for orexin/hypocretin in addiction.

Authors:  Stephen V Mahler; Rachel J Smith; David E Moorman; Gregory C Sartor; Gary Aston-Jones
Journal:  Prog Brain Res       Date:  2012       Impact factor: 2.453

3.  Functional analysis of a novel positive allosteric modulator of AMPA receptors derived from a structure-based drug design strategy.

Authors:  Jonathan E Harms; Morris Benveniste; John K F Maclean; Kathryn M Partin; Craig Jamieson
Journal:  Neuropharmacology       Date:  2012-06-23       Impact factor: 5.250

4.  A charge-inverting mutation in the "linker" region of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors alters agonist binding and gating kinetics independently of allosteric modulators.

Authors:  Jonathan E Harms; Morris Benveniste; Markus Kessler; Leslie M Stone; Amy C Arai; Kathryn M Partin
Journal:  J Biol Chem       Date:  2014-02-18       Impact factor: 5.157

5.  Interactions between VTA orexin and glutamate in cue-induced reinstatement of cocaine seeking in rats.

Authors:  Stephen V Mahler; Rachel J Smith; Gary Aston-Jones
Journal:  Psychopharmacology (Berl)       Date:  2012-03-13       Impact factor: 4.530

6.  Structural and functional analysis of two new positive allosteric modulators of GluA2 desensitization and deactivation.

Authors:  David E Timm; Morris Benveniste; Autumn M Weeks; Eric S Nisenbaum; Kathryn M Partin
Journal:  Mol Pharmacol       Date:  2011-05-04       Impact factor: 4.436

7.  Modulation of agonist binding to AMPA receptors by 1-(1,4-benzodioxan-6-ylcarbonyl)piperidine (CX546): differential effects across brain regions and GluA1-4/transmembrane AMPA receptor regulatory protein combinations.

Authors:  Kyle E Montgomery; Markus Kessler; Amy C Arai
Journal:  J Pharmacol Exp Ther       Date:  2009-08-28       Impact factor: 4.030

8.  Factors affecting guanine nucleotide binding to rat AMPA receptors.

Authors:  Kyle Montgomery; Erika Suzuki; Markus Kessler; Amy C Arai
Journal:  Brain Res       Date:  2007-08-16       Impact factor: 3.252

9.  Probing the allosteric modulator binding site of GluR2 with thiazide derivatives.

Authors:  Christopher P Ptak; Ahmed H Ahmed; Robert E Oswald
Journal:  Biochemistry       Date:  2009-09-15       Impact factor: 3.162

10.  Gating motions underlie AMPA receptor secretion from the endoplasmic reticulum.

Authors:  Andrew C Penn; Stephen R Williams; Ingo H Greger
Journal:  EMBO J       Date:  2008-10-16       Impact factor: 11.598

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.